PCSK9 Therapeutics and Cholesterol Optimization: On The Edge of An Era?
Transatlantic Dialogues on Controversies in Contemporary Cardiology 2016, Rome
When and how should we start PCSK9 inhibitors in 2016?
In a dialogue, Jorge Plutzky and Erik Stroes explored to what extend we are at the edge of an era, considering the advent of PCSK9 inhibiting therapy. They discuss how this can impact clinical practice.
Brigham and Women’s Transatlantic Dialogues on Controversies in Contemporary Cardiology
This lecture is part of a special educational symposium exploring controversies in cardiovascular risk management and compared and contrasted best common practices and guidelines on both sides of the Atlantic. American and European experts discussed novel insights from basic and translational cardiovascular science in the context of ongoing and future clinical studies
The program is an initiative of research leaders from the Brigham and Women’s Hospital, Boston, USA in collaboration with the PACE foundation.
Jorge Plutzky, MD – Director of the Vascular Disease Prevention Program, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Erik SG Stroes, MD – Professor of Vascular Medicine, AMC Amsterdam, The Netherlands
Faculty did not receive an honorarium for their lectures